Senseonics Holdings, Inc. Revenue Disclosure

4. Revenue Recognition

​

Revenues by geographic region

​

The following table sets forth net revenues derived from the Company’s two primary geographical markets, the United States and outside of the United States, based on the geographic location to which the Company delivers the product, for the years ended December 31, 2025 and 2024:

​

​

Contract Assets

​

Contract assets consist of unbilled receivables from customers and are recorded at net realizable value. Included in accounts receivable, net as of December 31, 2025 and December 31, 2024 are unbilled accounts receivable of $2.1 million and less than $0.1 million, respectively, which are related to the timing of billings. Included in accounts receivable – related parties, net are unbilled accounts receivable of $2.0 million and $0.9 million for the periods ended December 31, 2025 and 2024, respectively, which are related to revenue share variable consideration from the Commercialization Agreement. The Company expects to invoice and collect all unbilled accounts receivable within twelve months.

​

Concentration of Revenues and Customers

​

A significant portion of the Company’s revenue is derived from one customer, Ascensia. For the year ended December 31, 2025 and 2024, sales to Ascensia accounted for 53% and 82% of total revenue, respectively.

​

A portion of the Company’s revenue is earned via consignment arrangements with healthcare providers. For the years ended December 31, 2025 and 2024, sales under consignment arrangements accounted for 41% and 15% of total revenue, respectively. Ascensia earns a commission on sales made through these consignment arrangements for the support provided by their sales reps and commercial organization. Revenues for these corresponding periods represent sales of sensors, transmitters and miscellaneous Eversense System components.

​

Termination and Transition of the Commercialization Agreement

​

On September 3, 2025, the Company and Ascensia entered into a memorandum of understanding related to the transition of commercial operations for Eversense from Ascensia back to the Company. On December 31, 2025, the parties executed a Master Asset Purchase Agreement, pursuant to which the Company acquired certain U.S. commercial assets and assumed certain related liabilities, with the transaction closing on January 1, 2026. In connection with the agreement, the parties entered into an Amended and Restated Collaboration and Commercialization Agreement (the “A&R Commercialization Agreement”), which terminated Ascensia’s rights to market Eversense products in the United States and made Ascensia’s European commercialization rights non-exclusive.

​

Following the U.S. Closing, Ascensia has no further rights to revenues from sales of Eversense products in the United States, and effective January 1, 2026, the Company is entitled to 100% of revenues from sales in the European

Territories, subject to transitional arrangements. As a result of the termination and modification of the arrangement, the Company reassessed its remaining performance obligations and adjusted related contract assets and contract liabilities in accordance with ASC 606. In connection with the termination, the Company accepted the return of certain unsold inventory held by Ascensia, reversed $0.4 million of revenue, and recorded the returned inventory at its estimated net realizable value.